A liposome based platelet substitute, the plateletsome, with hemostatic efficacy.
The complexity of platelet mediated hemostasis has hindered development of a platelet substitute for transfusion therapy. In the current study, the hemostatic efficacy of a liposome based modality, the plateletsome, is demonstrated. A deoxycholate extract of a platelet membrane fraction, with a minimum of 15 proteins including GPIb, GPIIb-IIIa and GPIV/III, was incorporated into sphingomyelin: phosphatidylcholine: monosialylganglioside or egg phosphatide small unilamellar vesicles by reverse-phase/sonication and French press extrusion. These plateletsomes decreased bleeding by 67% in the tail bleeding time in rats made thrombocytopenic (platelets < 30,000/microliters) with external irradiation (7-9Gy) by Cesium source. Efficacy was also demonstrated in the thrombocytopathic, Fawn-Hooded rat, but to a lesser extent than in the thrombocytopenic animals. Direct plateletsome infusion to the tail wound was more effective than systemic administration for all effective preparations. On post-mortem examination, no pathologic thrombi were detected by gross and histopathologic examination of the lungs, livers, kidneys, or spleens of thrombocytopenic or normal animals after plateletsome infusion. No evidence of intravascular coagulation, monitored by levels of circulating fibrinogen and platelet counts, was observed when plateletsomes were administered intravenously to rabbits. No deleterious effect, either inhibition or hyperaggregability, on platelet aggregation studies in vitro was observed. While further refinements are clearly required, this study indicates that liposomes bearing specific platelet proteins may provide a basis for a clinically applicable platelet substitute.
Rybak
M E
ME
Division of Hematology, University of Massachusetts Medical Center, Worcester 01655.
Renzulli
L A
LA
D000818:Animals; D001760:Bleeding Time; D001791:Blood Platelet Disorders / Q000209:etiology / Q000628:therapy*; D001798:Blood Proteins / Q000008:administration & dosage*; D001802:Blood Substitutes / Q000494:pharmacology*; D004195:Disease Models, Animal; D004337:Drug Carriers; D006470:Hemorrhage / Q000209:etiology / Q000628:therapy*; D006490:Hemostatics / Q000494:pharmacology*; D008051:Lipid Bilayers; D008081:Liposomes; D008297:Male; D011833:Radiation Injuries, Experimental / Q000628:therapy; D051381:Rats; D011919:Rats, Inbred Strains; D017207:Rats, Sprague-Dawley; D013921:Thrombocytopenia / Q000209:etiology / Q000628:therapy*
D001798:Blood Proteins; D001802:Blood Substitutes; D004337:Drug Carriers; D006490:Hemostatics; D008051:Lipid Bilayers; D008081:Liposomes